[{"id":"cce0df20-21d8-4bec-947f-b02d39935805","acronym":"ARST2031","url":"https://clinicaltrials.gov/study/NCT04994132","created_at":"2023-08-27T06:10:56.547Z","updated_at":"2025-02-25T14:08:23.955Z","phase":"Phase 3","brief_title":"A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma","source_id_and_acronym":"NCT04994132 - ARST2031","lead_sponsor":"Children's Oncology Group","biomarkers":" FOXO1","pipe":"","alterations":" ","tags":["FOXO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • vincristine • dactinomycin • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-18"},{"id":"64fbfa8e-e3d5-4527-8e70-e669cf683ef4","acronym":"MOVIE","url":"https://clinicaltrials.gov/study/NCT03518606","created_at":"2021-01-18T17:19:19.354Z","updated_at":"2025-02-25T15:07:35.561Z","phase":"Phase 1/2","brief_title":"Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT03518606 - MOVIE","lead_sponsor":"UNICANCER","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Completed","enrollment":" Enrollment 126","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 12/19/2024","study_completion_date":" 12/19/2024","last_update_posted":"2025-01-15"},{"id":"8c8ff781-f391-42de-9882-e4814d7bf8ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03887130","created_at":"2021-01-18T19:09:12.750Z","updated_at":"2024-07-02T16:35:07.040Z","phase":"Phase 2","brief_title":"Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer","source_id_and_acronym":"NCT03887130","lead_sponsor":"Pierre Fabre Medicament","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • docetaxel • capecitabine • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Completed","enrollment":" Enrollment 152","initiation":"Initiation: 03/27/2007","start_date":" 03/27/2007","primary_txt":" Primary completion: 04/18/2013","primary_completion_date":" 04/18/2013","study_txt":" Completion: 04/18/2013","study_completion_date":" 04/18/2013","last_update_posted":"2024-04-30"},{"id":"0ac2e887-fadd-46a5-ab74-27b50f021611","acronym":"OPTIMAL\u003e60","url":"https://clinicaltrials.gov/study/NCT01478542","created_at":"2021-01-18T06:10:12.656Z","updated_at":"2024-07-02T16:35:07.367Z","phase":"Phase 3","brief_title":"OPTIMAL\u003e60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine","source_id_and_acronym":"NCT01478542 - OPTIMAL\u003e60","lead_sponsor":"Universität des Saarlandes","biomarkers":" ALK • CD20","pipe":" | ","alterations":" ALK positive","tags":["ALK • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Marqibo (vincristine liposomal)"],"overall_status":"Completed","enrollment":" Enrollment 1152","initiation":"Initiation: 11/01/2011","start_date":" 11/01/2011","primary_txt":" Primary completion: 01/18/2024","primary_completion_date":" 01/18/2024","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2024-04-26"},{"id":"d9205d85-be27-4b6c-84a5-c85c6627b25a","acronym":"NCI-2018-01198","url":"https://clinicaltrials.gov/study/NCT03136146","created_at":"2021-01-18T15:27:28.397Z","updated_at":"2024-07-02T16:35:12.329Z","phase":"Phase 2","brief_title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","source_id_and_acronym":"NCT03136146 - NCI-2018-01198","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • cyclophosphamide • etoposide IV • clofarabine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Marqibo (vincristine liposomal) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-03-29"},{"id":"6b069ddb-3d44-4c51-aafc-c9dbf27dc3ef","acronym":"AALL0433","url":"https://clinicaltrials.gov/study/NCT00381680","created_at":"2021-01-18T01:19:36.490Z","updated_at":"2024-07-02T16:35:12.895Z","phase":"Phase 3","brief_title":"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00381680 - AALL0433","lead_sponsor":"Children's Oncology Group","biomarkers":" MYC","pipe":" | ","alterations":" MYC translocation","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Kidrolase (L-asparaginase) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 275","initiation":"Initiation: 03/01/2007","start_date":" 03/01/2007","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2024-03-26"},{"id":"a785836b-20b0-471e-881f-8f79bcff309e","acronym":"NCI-2022-03576","url":"https://clinicaltrials.gov/study/NCT05359237","created_at":"2024-03-23T02:35:33.454Z","updated_at":"2024-07-02T16:35:13.188Z","phase":"","brief_title":"Vincristine Pharmacokinetics in Infants","source_id_and_acronym":"NCT05359237 - NCI-2022-03576","lead_sponsor":"Children's Oncology Group","biomarkers":" CYP3A4 • CYP3A5","pipe":"","alterations":" ","tags":["CYP3A4 • CYP3A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vincristine"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-03-22"},{"id":"94f2c520-fdab-4936-980c-693760a72522","acronym":"METEORA-II","url":"https://clinicaltrials.gov/study/NCT02954055","created_at":"2021-01-18T14:30:32.840Z","updated_at":"2024-07-02T16:35:17.646Z","phase":"Phase 2","brief_title":"MEtronomic TrEatment Option in Advanced bReast cAncer","source_id_and_acronym":"NCT02954055 - METEORA-II","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • capecitabine • cyclophosphamide • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 09/13/2017","start_date":" 09/13/2017","primary_txt":" Primary completion: 11/17/2021","primary_completion_date":" 11/17/2021","study_txt":" Completion: 11/23/2022","study_completion_date":" 11/23/2022","last_update_posted":"2024-02-26"},{"id":"23e2bcb5-1612-4e8c-afcb-bd63c8997ee0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04388839","created_at":"2023-08-27T06:10:27.849Z","updated_at":"2024-07-02T16:35:18.394Z","phase":"Phase 2","brief_title":"Evolutionary Therapy for Rhabdomyosarcoma","source_id_and_acronym":"NCT04388839","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" FOXO1","pipe":"","alterations":" ","tags":["FOXO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • irinotecan • vincristine • vinorelbine tartrate • dactinomycin • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 09/27/2020","start_date":" 09/27/2020","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-02-21"},{"id":"deee903e-5930-44d3-b25f-08f62a96eb65","acronym":"","url":"https://clinicaltrials.gov/study/NCT02564484","created_at":"2022-01-06T00:56:08.040Z","updated_at":"2024-07-02T16:35:29.503Z","phase":"","brief_title":"iPSC Neurons From Adult Survivors of Childhood Cancer Who Have Persistent Vincristine-Induced Neuropathy","source_id_and_acronym":"NCT02564484","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CEP72","pipe":"","alterations":" ","tags":["CEP72"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vincristine"],"overall_status":"Suspended","enrollment":" Enrollment 200","initiation":"Initiation: 02/08/2016","start_date":" 02/08/2016","primary_txt":" Primary completion: 05/12/2021","primary_completion_date":" 05/12/2021","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2023-11-13"},{"id":"45849cd8-b4d5-492c-aedb-5c1939de63b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04265274","created_at":"2021-01-18T20:43:08.046Z","updated_at":"2024-07-02T16:35:34.452Z","phase":"Phase 2","brief_title":"Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.","source_id_and_acronym":"NCT04265274","lead_sponsor":"National Cancer Institute, Slovakia","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • vinorelbine tartrate"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2023-10-06"},{"id":"f3babfe8-bc92-4caa-90a6-a8f28168e283","acronym":"","url":"https://clinicaltrials.gov/study/NCT05823623","created_at":"2023-04-21T15:04:29.768Z","updated_at":"2024-07-02T16:35:36.955Z","phase":"Phase 2","brief_title":"Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer","source_id_and_acronym":"NCT05823623","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • Cipterbin (inetetamab) • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/13/2022","start_date":" 02/13/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-09-14"},{"id":"99deeabc-01ac-4512-acfb-0ee835276399","acronym":"","url":"https://clinicaltrials.gov/study/NCT00846430","created_at":"2021-01-18T03:13:18.115Z","updated_at":"2024-07-02T16:35:38.602Z","phase":"Phase 2","brief_title":"Medical Treatment of \"High-Risk\" Neurofibromas","source_id_and_acronym":"NCT00846430","lead_sponsor":"Spectrum Health Hospitals","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • vincristine • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 04/01/2017","primary_completion_date":" 04/01/2017","study_txt":" Completion: 05/01/2017","study_completion_date":" 05/01/2017","last_update_posted":"2023-08-30"},{"id":"fa87048f-420f-406b-8c99-62a5161df0e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015126","created_at":"2023-08-29T16:10:04.804Z","updated_at":"2024-07-02T16:35:38.733Z","phase":"","brief_title":"Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT06015126","lead_sponsor":"Yan Xue","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/05/2022","start_date":" 10/05/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-08-29"},{"id":"d160a602-9e58-45a8-8e2b-46a9f6adfadd","acronym":"VEX","url":"https://clinicaltrials.gov/study/NCT04304352","created_at":"2021-01-18T20:52:33.096Z","updated_at":"2024-07-02T16:35:44.461Z","phase":"Phase 2","brief_title":"Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT04304352 - VEX","lead_sponsor":"European Institute of Oncology","biomarkers":" ER","pipe":" | ","alterations":" HER-2 overexpression","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • cyclophosphamide • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 07/29/2011","start_date":" 07/29/2011","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-06-28"},{"id":"790ce6b7-44f9-4447-9759-09e1b262a8bf","acronym":"ECOG-ACRIN EA9152","url":"https://clinicaltrials.gov/study/NCT03504644","created_at":"2021-01-18T17:15:14.614Z","updated_at":"2024-07-02T16:35:44.927Z","phase":"Phase 1/2","brief_title":"Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03504644 - ECOG-ACRIN EA9152","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Marqibo (vincristine liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2023-06-23"},{"id":"035efbd5-6fee-46bb-9159-ec783a6144a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05747326","created_at":"2023-02-28T13:01:22.187Z","updated_at":"2024-07-02T16:35:54.527Z","phase":"Phase 2","brief_title":"Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer","source_id_and_acronym":"NCT05747326","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2023-02-28"},{"id":"7d68e07b-11ee-4609-9459-b4a8e162aed2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454165","created_at":"2021-01-18T17:01:54.498Z","updated_at":"2024-07-02T16:35:58.227Z","phase":"Phase 1","brief_title":"A Study of BNC105P Combined With Ibrutinib","source_id_and_acronym":"NCT03454165","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" BCL2 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression","tags":["BCL2 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • BNC105"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 03/09/2018","start_date":" 03/09/2018","primary_txt":" Primary completion: 01/14/2021","primary_completion_date":" 01/14/2021","study_txt":" Completion: 01/14/2021","study_completion_date":" 01/14/2021","last_update_posted":"2023-01-04"},{"id":"9b8f0668-89c2-4a17-b398-80a6f02ea55e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01865045","created_at":"2021-01-18T08:20:35.723Z","updated_at":"2024-07-02T16:36:04.175Z","phase":"","brief_title":"Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients","source_id_and_acronym":"NCT01865045","lead_sponsor":"Armando Santoro, MD","biomarkers":" BRCA1 • TUBB3","pipe":" | ","alterations":" BRCA1 expression • TUBB3 expression","tags":["BRCA1 • TUBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 expression • TUBB3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vinorelbine tartrate"],"overall_status":"Completed","enrollment":" Enrollment 150","initiation":"Initiation: 11/01/2012","start_date":" 11/01/2012","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2022-09-10"},{"id":"9498000e-e76e-48a5-8403-624b16296410","acronym":"","url":"https://clinicaltrials.gov/study/NCT00567567","created_at":"2021-01-18T02:04:15.818Z","updated_at":"2024-07-02T16:36:11.330Z","phase":"Phase 3","brief_title":"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma","source_id_and_acronym":"NCT00567567","lead_sponsor":"Children's Oncology Group","biomarkers":" CD8 • MYCN • UGT1A1 • CD4","pipe":" | ","alterations":" MYCN amplification • UGT1A1*1*1","tags":["CD8 • MYCN • UGT1A1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • topotecan • melphalan • Marqibo (vincristine liposomal) • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 665","initiation":"Initiation: 11/05/2007","start_date":" 11/05/2007","primary_txt":" Primary completion: 02/27/2015","primary_completion_date":" 02/27/2015","study_txt":" Completion: 03/31/2022","study_completion_date":" 03/31/2022","last_update_posted":"2022-04-28"},{"id":"2c8c5bbf-03ea-4215-b0ce-72d0bc1d14ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT02607215","created_at":"2021-01-18T12:39:48.992Z","updated_at":"2024-07-02T16:36:11.762Z","phase":"Phase 2","brief_title":"Platinum Rechallenge in Patients With Platinum-sensitive mTNBC","source_id_and_acronym":"NCT02607215","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vinorelbine tartrate"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-04-20"},{"id":"4e2624b6-f37c-4cef-a490-8ac1b580742e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03851081","created_at":"2021-01-18T19:00:50.012Z","updated_at":"2024-07-02T16:36:17.836Z","phase":"Phase 1b/2","brief_title":"Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03851081","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin) • Marqibo (vincristine liposomal)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/21/2021","start_date":" 01/21/2021","primary_txt":" Primary completion: 01/21/2023","primary_completion_date":" 01/21/2023","study_txt":" Completion: 01/21/2024","study_completion_date":" 01/21/2024","last_update_posted":"2022-01-28"},{"id":"a8d3d321-676b-43b3-809c-1d0358c715d7","acronym":"PEN-221-001","url":"https://clinicaltrials.gov/study/NCT02936323","created_at":"2021-02-11T16:53:16.188Z","updated_at":"2024-07-02T16:36:19.555Z","phase":"Phase 1/2","brief_title":"PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers","source_id_and_acronym":"NCT02936323 - PEN-221-001","lead_sponsor":"Tarveda Therapeutics","biomarkers":" SSTR • SSTR2","pipe":" | ","alterations":" SSTR positive • SSTR2 positive","tags":["SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nendratareotide uzatansine (PEN-221)"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 12/08/2016","start_date":" 12/08/2016","primary_txt":" Primary completion: 07/31/2020","primary_completion_date":" 07/31/2020","study_txt":" Completion: 02/25/2021","study_completion_date":" 02/25/2021","last_update_posted":"2021-12-14"},{"id":"0c4ed01f-14ce-4638-8fa4-fe09d03ac925","acronym":"","url":"https://clinicaltrials.gov/study/NCT00000954","created_at":"2021-01-29T06:52:47.531Z","updated_at":"2025-02-25T14:22:42.205Z","phase":"Phase 1/2","brief_title":"A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma","source_id_and_acronym":"NCT00000954","lead_sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • vincristine • bleomycin"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 09/01/1996","study_completion_date":" 09/01/1996","last_update_posted":"2021-10-29"}]